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ABSTRACT 
 
Reversing Heart Failure: Diastolic Recoil in a Proposed  
Cardiac Support Device. (April 2010) 
 
Timothy Daniel Snowden 
Department of Biomedical Engineering 
Texas A&M University 
 
Research Advisor: Dr. John C. Criscione 
Department of Biomedical Engineering 
 
Congestive heart failure (CHF) holds millions in the grip of an endless cycle of 
decreased cardiac output and degenerative remodeling, often with little hope of recovery.  
Diastolic dysfunction, or failure of the heart to properly fill, is a contributing factor to all 
cases of CHF and is the sole cause of many cases.  By storing energy during systole that 
can be released during diastole, the addition of a diastolic recoil component to an 
existing systolic support device could aid in inducing restorative remodeling and, thus, 
interrupt the downward spiral of heart failure. 
 
In this study we use an indicator of diastolic function—the end-diastolic pressure-
volume relationship (EDPVR)—to demonstrate in vitro the ability of a prototype device 
to positively impact the entire heart cycle.  The support device alone shifts the EDPVR 
of a model heart towards smaller volumes.  When the diastolic recoil component is 
employed, the EDPVR is shifted towards lower pressures at low volumes, indicating 
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stiffer diastolic recoil.  We conclude the device provides bi-phasic support of our model 
heart, constraining over-filling of the ventricles and augmenting ventricular recoil. 
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NOMENCLATURE 
 
Afterload The force which the heart must work against to eject 
blood, determined by the amount of blood in the ventricles 
prior to contraction. 
Akinetic myocardium Myocardium that is not contracting. 
Cardiomyopathic Harmful to the heart muscle. 
CAO Coronary Artery Occlusion.  Complete blockage of one of  
 the blood vessels feeding the myocardium. 
CHD Coronary Heart Disease.  A disease of the coronary  
arteries that can lead to arterial occlusion and myocardial 
infarction.  Also known as CAD or Coronary Artery 
Disease. 
Coronary Pertaining to the heart. 
Dyskinetic myocardium Myocardium that is contracting abnormally or bulging. 
Edema Swelling or inflammation resulting from accumulation of 
fluid in a tissue, organ, or body region. 
EDPVR End-Diastolic Pressure-Volume Relationship.  An 
indicator of the heart‘s diastolic properties. 
Fibroblasts Cells that produce collagen and other extracellular matrix 
‗fibers.‘ 
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Hyperplasia Abnormal enlargement of a tissue or organ due to 
replication of its cells, which are maintaining a relatively 
constant size; as opposed to hypertrophy. 
Hypertrophy Abnormal enlargement of a tissue or organ due to 
enlargement of its cells; as opposed to hyperplasia. 
Hypotension Low blood pressure. 
Ischemia Restricted blood flow to a tissue, organ, or region of 
interest. 
Innvervation Stimulation of a nerve. 
Manometer A pressure gauge consisting of a column of liquid 
displaced by changes in pressure. 
MI Myocardial Infarction, commonly known as a heart attack. 
Myocardium Heart muscle. 
Myocyte Muscle cell. 
Neurohumor Biochemical produced by a neuron to affect a neuron, 
muscle, or gland. 
Perfusion Blood flow to a tissue, organ, or region of interest. 
Pericardium A membrane that surrounds the heart and roots of the 
  major blood vessels. 
Resection Surgical removal of a section of a tissue or organ.  
Systemic Pertaining to the body as a system. 
Tachycardia Abnormally rapid heart rate.  
  x 
Vasoconstriction Decrease in diameter of blood vessels due to contraction of 
the smooth muscle cells in the vessel wall. 
Vasodilation Increase in diameter of blood vessels due to relaxation of 
the smooth muscle cells in the vessel wall. 
  xi 
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Credited with 7.2 million deaths across the globe each year, coronary heart disease 
(CHD) possesses the dubious honor of being the world‘s leading killer [1].  Narrowing 
of the lumen of coronary arteries reduces blood supply to the heart, leading to ischemia, 
injury, and infarction.  It is not hard to imagine the level of damage that can be done by 
restricting the nutrient delivery to and waste removal from one of the body‘s most vital 
organs.  An ‗index event‘ such as coronary artery occlusion (CAO) can set off one of the 
best known results of CHD: myocardial infarction (MI).   
 
Those who escape the ‗silent killer‘s‘ initial attack rarely realize the consequences of 
survival.  The localized necrosis of myocardial cells, from which myocardial infarction 
derives its name, naturally results in a decrease of the cardiac muscle‘s capabilities and, 
thus, decreased cardiac output.  Decreased cardiac output triggers the body‘s 
compensatory mechanisms, placing elevated demands on the heart.  The continuous 
level of mechanical strain on the heart resulting from its attempts to meet these elevated 
demands is thought to induce degenerative left ventricular remodeling, and ultimately 
alter the left ventricle‘s shape and structure.  Cardiac function, in turn, is negatively 
_______________ 
This thesis follows the style of Journal of Medical Devices. 
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impacted, resulting in systolic and diastolic dysfunction and further output reduction, 
creating a vicious downward cycle illustrated in Figure 1.  Ultimately, this unceasing 
cycle causes congestive heart failure (CHF) to develop, the term used to describe 
insufficient blood output from the heart and corresponding reduced blood flow, a 
compensating increase in blood volume, and the resulting congestion of the veins and 
lungs, leading to further deterioration of the heart. 
 
It should be noted that while, for very good reason, CAOs and MIs are well known, and 
were used here to illustrate the genesis of the heart failure cycle, they are by no means 
the only pathway followed by CHD or the sole means of initiating heart failure.  
Additionally, although CHD is one of the major culprits in heart failure, any disease that 
results in a continually depressed level of cardiac output can serve to begin the cycle. 
 
Fig.  1  Heart failure and degenerative remodeling cycle with example 
index event. 
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CHF is classified as either systolic dysfunction (failure of the ventricles to adequately 
eject blood) CHF or diastolic dysfunction CHF.  Diastolic dysfunction—or failure of the 
ventricles to properly fill—is the sole cause of CHF for 40-60% [2] of the nearly 5 
million Americans suffering from the disease [3], and is a contributing factor in all cases 
[2].  Current treatments for heart failure do not fully exploit the mechanics involved for 
either systolic or diastolic dysfunction, leaving a key component of disease and recovery 
unaddressed.  A device developed to induce restorative remodeling by providing both 
active compression assistance and systolic support has been prototyped in John 
Criscione‘s cardiac mechanics lab at Texas A&M University.  The device is intended to 
be implanted in a minimally invasive surgery—eliminating the need for open-heart 
surgery—adjusted during healing, and ultimately explanted once the heart is normal.   
 
The latest conception of this device includes the addition of a flexible metal alloy frame 
that stores energy during systole and releases it during diastole, serving to strengthen 
diastolic recoil and address diastolic dysfunction.  With systolic and diastolic 
components, the device provides support for the entire heart cycle, and is intended to 
induce restorative remodeling of the left ventricle by partially relieving the abnormal 
mechanical loads on the heart.  By preventing further degenerative remodeling while 
reversing existing damage, the device would interrupt the malicious cycle described 
previously, and could be used in conjunction with therapies designed to treat the initial 
condition to eventually restore normal heart function.  In what follows, we use the end-
diastolic pressure-volume relationship (EDPVR), a known indicator of diastolic heart 
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function, to provide an initial proof of concept of the diastolic recoil component and the 
device‘s ability to provide biphasic modulation of the entire heart cycle. 
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CHAPTER II 




The example in the previous chapter in which coronary heart disease led to coronary 
artery occlusion and myocardial infarction illustrates one of the many possible index 
events or processes leading to CHF.  In reality, any disease or condition that damages 
myocytes or negatively affects the contractile ability of the myocardium could serve as a 
factor leading to CHF.  In addition to CHD, these risk factors include hypertension, 
diabetes mellitus, congenital heart disease, valvular heart disease, viral infections, 
infiltrative disease processes, or genetic cardiomyopathies [4, 5].  The members of this 
wide range of disorders share very little in common; some strike rapidly, others 
gradually; some primarily affect the cardiovascular system, while others primarily target 
other organs or regions of the body.  Regardless of their diversity, one essential 
characteristic is shared by each of these varying disorders: suppressed heart function and 
the resulting reduction in cardiac output. 
 
As cardiac output diminishes, compensatory cascades are activated in an attempt to 
restore proper perfusion and maintain homeostasis.  Decreased stroke volume and 
cardiac output naturally reduces blood pressure, resulting in suppressed coronary and 
systemic perfusion.  Insufficient systemic perfusion causes vasoconstriction and fluid 
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retention as the renin-angiotensin-aldosterone (RAA) pathway upregulates angiotensin II 
(the most potent human vasoconstrictor known), vasopressin and aldosterone (both of 
which increase fluid reabsorption in the kidneys) in an attempt to restore adequate blood 
flow [6, 7].  Vasoconstriction ameliorates hypotension, and elevated blood volume 
increases cardiac output via increased preload and afterload of the heart.  Intensified 
sympathetic stimulation elevates norepinephrine levels, reinforcing vasoconstriction 
through increased binding to α receptors [8], and activating β1 receptors responsible for 
upregulating calcium ion activity in the myocardium, effectively increasing contractile 
force and frequency [9].  Together, these responses serve as an acute adaptation to 
stabilize cardiac output. 
 
Persistent maladaptation 
In addition to their stabilizing effects, these adaptive mechanisms also bring about 
negative consequences.  The adrenergic response, for example, one of the strongest of 
the body‘s compensatory cascades, also induces cardiomyocyte hypertrophy and 
apoptosis, myocyte damage, and fibroblast hyperplasia [4].  In the short term, these 
effects are overshadowed by the immediately beneficial effects previously described.  If 
these adaptive processes persist, however, the good effects gradually are subdued by 
those harming the heart, and the response becomes maladaptive and cardiomyopathic. 
Increased peripheral resistance due to vasoconstriction combines with greater afterload 
to elevate the load on the left ventricle, exacerbating the reduced myocardial 
functionality caused by decreased coronary perfusion.  As the increased workload of the 
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heart under suboptimal conditions continues, the myocardium begins to structurally 
change in an effort to reduce the abnormal stresses it is experiencing.  The myocytes 
themselves lose myofilaments, adjust the relative expressions of heavy myosin chain 
types, alter cytoskeletal proteins, alter excitation contraction coupling, and become less 
responsive to adrenergic stimulation.  The left ventricle particularly alters geometry, as it 
dilates and begins shifting from a prolate ellipsoid to a spherical shape, thinning its wall 
in the process [4].   
 
The structural changes to the ventricles and myocardium, referred to as degenerative (or 
maladaptive) remodeling, further aggravate the problem.  These alterations further 
increase the burdens on the heart, triggering intensified neurohormonal compensatory 
mechanisms, resulting in increased loads on the heart and escalated degenerative 
remodeling [4, 5].  For a time symptoms may be suppressed by the compensatory effects 
of the temporary adaptive mechanisms; however, as the cycle continues to progress 
unheeded and the heart becomes increasingly dysfunctional, symptoms begin to present 
[4]. 
 
As the cycle continues and the disease progresses, damage reaching throughout the body 
ensues.  Continued dilation and distortion of the ventricle, for instance, affects the 
papillary muscles attached to the mitral valve via the chordae tendenae.  Enlargement of 
the ventricles displaces the papillary muscles, distorting the mitral valves and resulting 
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in mitral regurgitation (MR) [10].  Mitral regurgitation further diminishes cardiac 
efficiency, compounding the already heightened demand on the heart. 
 
Another common and important symptom is blood congestion in the pulmonary system, 
caused by increased pressure in the left ventricle from greater blood volume and 
degenerative remodeling-induced weakening.  The lungs and airways become 
edematous, reducing compliance, obstructing airways, and reducing lung capacity: all 
factors contributing to magnify the work required to breathe and, thus, the demand for 
blood flow to the muscles responsible for breathing.  The altered distribution of blood to 
critical organs particularly impacts the renal system; increased demand from respiratory 
muscles combines with high sympathetic nervous system tone to seriously reduce renal 
perfusion and lead to renal dysfunction [6]. 
 
Diastolic dysfunction 
The impact of these various adaptations and maladaptations on systolic function is 
intuitive.  As output decreases, directly affecting the myocardium through decreased 
coronary perfusion, and indirectly affecting the heart by various mechanisms designed to 
restore systemic perfusion, the heart is placed under increasing stresses.  It is not hard to 
visualize the myocytes in the ventricles laboring under increased demands and decreased 
supplies. 
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What is much harder to comprehend is the effect of the various maladaptations on 
diastolic function.  To the untrained enquirer, it would almost seem as if the increased 
pressures and loads would ensure excellent diastolic function by filling, if not 
overfilling, the ventricular chambers.  Such is obviously not the case, however, when it 
is considered that diastolic dysfunction dominates approximately half of the heart failure 
cases and is evident to some extent in all cases.  Diastolic dysfunction is described by 
Gaasch and Zile as implying ―that the myofibrils do not rapidly or completely return to 
their resting length; the ventricle cannot accept blood at low pressures, and ventricular 
filling is slow or incomplete unless atrial pressure rises‖[11]. 
 
As should be expected, a multitude of factors are known to influence diastolic 
dysfunction.  Underlying mechanisms can affect the active relaxation process and the 
passive stiffness properties of the heart muscle.  One common mechanism affecting the 
cardiomyocyte is altered calcium ion homeostasis – possibly partially resulting from 
increased sympathetic tone – in which amplified calcium activity increases contractility, 
extending myocardial relaxation time [12, 13]. 
 
Another mechanism affects the viscoelasticity of the cardiomyocytes.  Titin is a 
cytoskeletal protein that acts as a viscoelastic spring to store energy during myocyte 
contraction and release it during relaxation.  Abnormal titin isoforms and distribution, 
possibly coupled with elevated microtubule (another cytoskeletal component) density 
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and distribution, adversely affect diastolic recoil by behaving as a viscous load and 
increasing viscoelastic stiffness [12, 13].   
 
Alteration of the extracellular matrix (ECM) is a third major mechanism.  Interstitial 
fibrosis is often associated with hypertrophy, as cardiac fibroblasts, activated in part by 
the RAA system, increase fibrillar collagen deposition and eventually lead to increased 
myocardial stiffness and reduced reserve flow in the coronary arteries.  Load and 
neurohumoral activation also increase collagen synthesis, in conjunction with a shift in 
the synthesis/degradation balance.  While not thought to be an initial cause, excessive 
sympathetic innervations increasing heart rate may induce tachycardia, reducing 
myocyte relaxation time and exacerbating existing diastolic dysfunction [12, 13]. 
 
These are only a few of the partially understood mechanobiological factors underlying 
the onset and progression of diastolic dysfunction.  Many more alterations have been 
identified and tentatively linked to diastolic dysfunction – shifts in the ADP/ADP ratio 
affecting the energetics of myocyte relaxation, effects of matrix metalloproteinases on 
collagen synthesis/degradation balance, or changes to the cyclic release of nitric oxide 
responsible for modulating myocardial relaxation and stiffness [13].  Regardless, from 
our sampling of the vast array of convoluted mechanisms controlling and impacting 
diastolic function we can gather that diastolic dysfunction is associated with 
degenerative remodeling of the left ventricle, particularly hypertrophy, and is likely 
caused, at least in part, by myocardial fibrosis and abnormal loads [14]. 
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Current approaches 
Almost as numerous as the mechanisms underlying heart failure are the approaches that 
have been developed to directly or indirectly address them.  Pharmacological treatments, 
surgical therapies, and mechanical devices are constantly being proposed, improved, or 
abandoned as our understanding of the heart and the plethora of associated systems and 




Fig.  2  Approaches to remediating heart failure. 
(* Denotes a largely obsolete approach) 
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Pharmacology 
Pharmacological therapies are usually employed as the first line of defense against 
decreased cardiac function in an effort to interrupt the adverse neurohormonal cascades.  
Beta-blockers are used to reduce elevated sympathetic tone; angiotensin II receptor 
blockers (ARB), angiotensin converting enzyme (ACE-I) inhibitors, and aldosterone 
(Aldo-I) inhibitors to combat upregulation of the RAA system; and diuretics to reduce 
fluid retention.  While these therapies, and others, have demonstrated a significant 
positive effect on morbidity and mortality, the extent to which they can retard disease 
progress is limited before the body begins desensitization to their actions and their side-
effects begin proving detrimental [4, 5, 15-17].  Current understanding of the 
mechanisms involved indicates that the limitations of pharmacological therapies is 
strongly linked to their failure to halt or reverse adverse structural and mechanical 




It is not surprising, then, that surgical techniques designed to amend underlying 
structural and mechanical problems have proliferated.  Ventricular reduction surgeries 
encompass several techniques designed to restore the ideal size and shape of the left 
ventricle in an effort to reduce stress and dyssynchrony and improve myocardial 
contraction.  The Batista procedure is one of the earlier attempts to restore cardiac 
function by surgically reshaping the left ventricle.  Batista removed a section of 
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functional myocardium in the left ventricular free wall, returning the left ventricle to a 
more ellipsoid shape.  Unfortunately, high failure rates and a failure to improve overall 
pump function led to an abandonment of this procedure by most hospitals [16, 18, 19]. 
 
Removal of dyskinetic scars (bulging regions of injured, dysfunctional tissue, often 
resulting from myocardial infarction), or aneurysmorophy, has become widely accepted, 
and is reported to consistently improve ventricular shape and function.  The resected 
area is often replaced with a patch in a technique called endoventricular patch plasty, or 
the ‗Dor procedure‘.  Akinetic scars (regions of non-functioning tissue) are also removed 
using this approach, but the benefits are much more controversial, as CABG and/or other 
surgery is normally performed simultaneously, eliciting doubt as to the role akinetic scar 
resection had in positive results [10, 16, 18]. 
 
Dynamic cardiomyoplasty is an obsolete surgery in which the latissimus dorsi muscle is 
wrapped around the heart and stimulated in synchrony with it in an effort to provide 
systolic support.  Although the technique was a failure in the sense that the skeletal 
muscle fatigued and was unable to maintain a significant level of systolic augmentation, 
it motivated the creation of an entire class of heart failure devices.  During trials, it was 
noticed that, regardless of synchronized stimulation of the skeletal muscle, that diastolic 
properties were improved, sometimes also enhancing cardiac performance, leading Kass, 
et al to postulate that the longissimus dorsi was actually acting as an elastic girdle and 
passively constraining the ventricles [17, 20].  
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Coronary artery bypass graft (CABG) surgery is used for heart failure patients with 
significant coronary artery stenosis and ample viable myocardium.  Although not 
directly addressing size or shape of the heart, CABG surgery can remove a problem 
triggering biochemical cascades – stenosis – and reverse left ventricular dilation, 
provided enough dysfunctional but still viable myocardium is present.  Mitral 
regurgitation repair or replacement is another common surgery performed 
simultaneously with ventricular repair, alteration, or device implantation [10]. 
 
Devices 
While providing valuable options for interrupting the destructive neurohormonal 
pathways and degenerative remodeling cycle, the surgeries just discussed have several 
disadvantages.  The Dor procedure, for example, has a wide variability in its 
effectiveness due to the highly subjective nature of determining the amount of tissue to 
remove and the final shape and size of the left ventricle.  Nearly all of the surgeries are 
major interventions that inherently carry a relatively high risk of mortality, and so are 
not undertaken lightly or immediately upon detection of remodeling and dysfunction.  
Neither do any of the surgeries directly address improvement of blood circulation, 
although several of the pharmacological therapies do – such as the vasodilators.  Finally, 
any combination of pharmacological and surgical intervention requires the failing heart 
to have the capability of maintaining adequate heart function while healing.  This leaves 
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several windows of opportunity for approaches that are minimally invasive, directly 
improve blood circulation, and/or support or replace heart function during healing. 
 
Active assist 
We have classified the most common classes of devices into two main groups: active 
and passive.  Active assist devices provided pumping energy to the heart.  This subclass 
contains one of the most widely used and well known group of heart devices – blood 
pumps.  This ubiquity should not be surprising, considering that their functions range 
from augmentation to replacement of the heart‘s primary responsibility of pumping 
blood.  Counter-pulsation assist devices, or intra-aortic balloon pumps (IABP) are 
catheter based pumps placed into the descending aorta, inflated during diastole, and 
deflated at the beginning of systole.  Providing mechanical support of circulation, they 
serve to increase coronary perfusion, balance myocardial oxygen supply and demand, 
and increase cardiac output and ejection fraction [6].   
 
When IABPs fail to satisfactorily augment circulation, ventricular support is often 
employed as the next logical step.  Left ventricular assist devices (LVAD) are employed 
to improve hemodynamic flow, although VADs can be classified as intra-, para-, and 
extracorporeal based on their implantability, and into pulsatile or continuous flow, and 
then further subdivided by the mechanism utilized.  LVADs have an impressive history 
of improving circulation and heart function, serving as both bridges to transplant and 
permanent support [6, 10, 16].   LVADs were one of the first devices recognized to 
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induce restorative remodeling; hemodynamic unloading was found to reverse ventricular 
dilation [21] as well as molecular remodeling, upregulating gene expression related to 
myocardial activity and increasing contractile strength of cardiomyocytes [22].  Hetzer, 
et al demonstrated that structural improvements and restored cardiac function could 
persist after gradual weaning from the LVAD [23], leading to both occasional 
implementation as bridges to recovery and development of newer devices based on the 
knowledge accumulated from their widespread investigation and use.  An ‗extreme 
version‘ of VADs, implantable total artificial hearts have been attempted, and marginally 
successful, but are indicated only in the most desperate cases [17]. 
 
The Anstadt cup is a device for direct cardiac compression, and consists of a rigid shell 
lined with a flexible diaphragm which is only fixed at the rim and the apex.  The 
diaphragm is then cyclically pressurized and physically compresses the heart, pumping 
blood and improving circulation while avoiding the problems associated with direct 
blood contact with the device.  Despite its apparent advantages, few long term trials have 
been performed and the device has not gained widespread usage [24, 25]. 
 
Passive support 
Passive support devices are fairly self-explanatory – a passive device constrains the 
heart, limiting growth and adverse remodeling, and possibly inducing restorative 
remodeling.  The motivation for these devices stems from the discovery that despite its 
purpose of augmenting systolic function, cardiomyoplasty provided passive elastic 
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support for the heart [20, 26].  The most direct application is a synthetic wrap for the 
ventricles, such as Acorn Cardiovascular‘s™ CorCap™, which was demonstrated to 
prevent progressive LV dilation and dysfunction, to decrease sphericity, and to limit 
functional mitral regurgitation [10, 16, 27].  The Myosplint® was another device which 
attempted to passively alter ventricular shape, but through flexible cords bisecting the 
ventricle and reducing sphericity, wall stress and mitral valve distortion [17].  
Unfortunately, the parent company, Myocor™, closed in 2008 and sold the rights to the 
device to a company with no plans for further development [28]. 
 
Diastolic recoil components are also passive, in the sense that they do not provide 
additional energy to the heart cycle; their purpose is to store energy during systole and 
return it to the heart during diastole to improve the decreased diastolic suction due to 
convective deceleration and diminished elastic recoil brought about by chamber 
remodeling [29].  The only currently known device is the ImCardia™ device developed 
by CorAssist Cardiovascular Ltd.  This device basically consists of springs implanted in 
the ventricular wall to augment recoil, and has demonstrated an ability to induce 
restorative remodeling [30]. 
 
Cardiac resynchronization 
Another therapy seeing increasing usage is cardiac resynchronization therapy (CRT), 
which uses a pacemaker to address electrical activation delays of the left ventricular free 
wall.  This delay causes portions of the ventricle to act against other portions, sloshing 
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blood horizontally rather than properly ejecting it.  CRT coordinates the septum and free 
wall by stimulating multiple loci – or resynchronizing the left ventricle.  While not 
directly modulating mechanics, this approach has been shown to improve ventricular 
performance and result in reduction of left ventricular size [17].  
 
 




Ultimately, the ideal therapy or combination of therapies would not only interrupt, but 
also reverse the progress of the disease process by removing the mechanisms that 
underlie neurohormonal cascades mediating the stabilizing responses responsible for 
long-term maladaptation and degenerative remodeling.  That is the aim of the proposed 
device. 
 
A prototype device developed by Dr. John Criscione and others couples a passive 
support device with an active assist component.  The device consists of a conical 
chamber that can be variably inflated with a fluid to reduce the size of the chamber‘s 
interior.  This chamber fits snugly over the ventricles.  A separate inflatable jacket fits 
around this device and is cyclically inflated in synchrony with systole.  Unpublished 
preliminary preclinical trials established the potential of this device to improve systolic 
performance by addressing the mechanical loads triggering biochemical processes 
inducing structural remodeling through a dual action of both supporting the ventricles 
with the passive chamber, constraining them from overfilling, and augmenting 
contraction of the heart with the pulsatile component, increasing cardiac output. 
 
The solution proposed consists of expanding this device‘s support activity to the entire 
heart cycle through the addition of a diastolic recoil component.  A flexible alloy frame 
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that compresses during systole and acts to transfer energy to the beginning of diastole is 
inserted into the systolic support chamber, creating a negative pressure gradient in the 
left ventricle that assists relaxation and augments ventricular filling.  Figure 3 pictures a 
prototype of this frame. 
 
Altogether, this device aims to address many of the problems with previous 
technologies.  By directly addressing the mechanics responsible for the neurohormonal 
pathways, it avoids the negative effects and reduced efficacy associated with prolonged 
pharmacological inhibition.  A collapsible device that can be implanted in a minimally 
invasive surgery, it eradicates the need for the major surgeries that so negatively impact 
the survival of patients with advanced heart failure.  The device is adjustable pre- and 
post-implantation, allowing the device to follow the shrinking size of the heart as proper 
size and shape are restored, maximizing efficacy and potential for final recovery.  
Because the device is implanted inside the pericardium, and so is secured to the 
 
 
Fig.  3  Recoil frame made of shape 
memory alloy. 
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ventricles by the vacuum existing between the pericardium and the heart, the device is 
not physically secured to the heart and can be removed once ventricular function is 
adequately restored.  Although some level of fibrosis is unavoidable, the multiple layers 
of the device should maintain the free movement of the heart by preventing the same 
surface from fibrosing to both the epicardium and pericardium. 
 
The project described in the following chapters is designed to demonstrate the ability of 
the support components of this device to simultaneously: 1) shift the filling curve of a 
laboratory model of the ventricles towards lower volumes (constrainment), and 2) induce 
negative pressures at low volumes, modeling the initial portion of the filling cycle.  
Figure 4 conceptually illustrates this response.  Demonstrating this bi-phasic action 
would indicate that the device holds great promise for modulating pathological 
mechanical loads on the ventricles and inducing restorative remodeling. 
 
Fig.  4  Conceptual EDPVR illustrating proposed bi-phasic response.  
Courtesy of Michael Moreno. 
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CHAPTER IV 
METHODS AND EXPERIMENTAL SETUP 
 
As can be inferred from the research goals, the entire focus of the laboratory portion of 
the project was to obtain EDPVR‘s from a model heart alone and with the two support 
components of the proposed device in action; thereby allowing comparisons to be drawn 
between EDPVR‘s in order to evaluate the potential effectiveness of each component. 
 
The project consisted of two phases.  In the first, a model was created to mimic the 
EDPVR of a human heart.  A model of the normal heart was chosen because the 
mechanics and response of the normal heart are better known and easier to model than 
the failing heart‘s complicating structural and mechanical alterations, and a model of the 
normal heart is sufficient to meet the goal of demonstrating the device‘s ability to effect 
a bi-phasic modulation of the heart cycle.  This model was used to set baseline values for 
later comparison to the results when the device was tested.  Once a satisfactory model 
was built, the device was tested using the experimental setup described in the remainder 
of the chapter. 
 
The experimental setup is conceptually very simple: pressure or volume was 
incremented, and therefore, known, while the corresponding change in the other variable 
(volume or pressure, respectively) was measured.  The results were then plotted to create 
an EDPVR.  At the outset of the project, volume was used as the independent variable, 
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and incrementally increased while the corresponding change in pressure was measured 
using a manometer.  This approach concentrated the readings in the low pressure region 
of the EDPVR, as incremental changes in volume led to major pressure changes as 
volume increased.  Additionally, because a small volume change could create a major 
change in pressure at high volumes, it was difficult to create stable, easily repeatable 
relationships. 
 
To avoid these problems, pressure was made the independent variable.  Pressure was 
incrementally changed by varying the difference in height between the model and a 
water reservoir.  The volume change in the water reservoir corresponding to each 
pressure change was measured, and the results plotted to create an EDPVR.  Figures 5 
and 6 illustrate this setup. 










Pressure Ring stand 
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Fig.  6  Close-up illustration of heart model, pericardial sac model, and cutaway device with diastolic 
recoil frame and inflated passive support chamber. 
 
 
Pressure readings were taken at 5 cmH2O intervals.  The heart has a normal left 
ventricular end-diastolic pressure of approximately 15 mmHg [31], or 20 cmH2O; thus, 
5cm intervals were determined to be sufficient to allow an accurate EDPVR to be 
obtained. 
 
In order to obtain an accurate comparison and eliminate as much error as possible, new 
baseline values of the heart model alone were taken at the beginning of every trial.  Once 
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recoil component.  Finally, the recoil component was inserted in the passive support 
device.  The three sets of EDPVRs gained can then be compared and the effects of each 
component – passive support and recoil support – determined. 
 
It is important to note that the device is not physically secured to the recoil component; 
therefore, the diastolic support component relies on the presence of a vacuum to cause 
the ventricle walls to adhere to the device and follow it outward when it recoils as the 
heart enters diastole.  In the body, the pericardial sac that surrounds the heart provides a 
vacuum.  In this experimental setup, the pericardial sac was modeled by a vacuum drawn 
in a sac placed around the heart model and device. 
 
 





An initial heart model, which Figure 7 depicts, utilized an internal solid plug to mimic 
the heart‘s shape and a compliant bladder surrounding the plug to mimic the heart‘s 
compliance and volume range.  This model yielded an EDPVR with a pressure range of 
about 16cmH2O over a 350mL volume range, as the plot in Figure 7 illustrates.  
Employing the empty support and recoil device caused the EDPVR to shift to the left, 
 


































Fig.  7  EDPVR’s and inset photograph (top left) of the initial heart model.  Note the non-
physiological spherical shape. 
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towards smaller volumes.  Increasing the volume in the systolic support chamber from 
50-100mL resulted in little response of the maximum heart volume.  Increasing the 
volume in the support chamber to 150mL and 200mL caused further leftward shifts of 
the EDPVR, ultimately reducing the volume at 25cmH2O by approximately 150mL.  
The device also modulated the small volume portion of the EDPVR, creating a 
maximum drop of about 25cmH2O from the model baseline.  This drop was reduced as 
the EDPVR was shifted leftward by the increased constraint of the support chamber.  It 
should be noted that the device used was a previous version of the current design, in 
which the recoil frame was in a separate chamber surrounding the support chamber.  
This chamber required pressurization to keep the diastolic recoil frame taut, in these tests 
160mL of air was used.  Additionally, the data was taken using the original method 
described in the previous chapter, in which volume was altered and the resulting 
pressure change was recorded. 
 
Current model 
The first model was replaced because its shape distorted into a sphere as it was filled.  
The new model consisted of a flexible, non-elastic shell that modeled both the shape and 
compliance of the heart, shown in Figure 8.  Figures 9 and 10 both contain baseline 
results of the new model, which show an EDPVR shape satisfactorily close to the ideal 
relationship. 
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Tests of the efficacy of the diastolic recoil component are contained in Figure 9.  The 
support device used in this trial, when empty, was the same size as the model heart; 
therefore, no constraint was expected, allowing the diastolic recoil component alone to 
be tested.  Additionally, in this trial the support chamber held only very low pressures, 
causing the only changes in volume between the unfilled and filled (20mL) support 
chamber to be at low pressures.  The experimental method used was the second method 
described in the previous chapter, in which pressure was incremented and the 
corresponding volume response was recorded.  Employment of the recoil device caused 
the beginning volume to increase by approximately 200mL. 
 
Fig.  8  Current heart model. 
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The biphasic response of the combined support and recoil device is shown in Figure 10.  
In these trials, which used the same method as the previously described experiments, 
employment of the empty support and recoil device caused a small leftward shift of 
approximately 20mL.  Filling the support chamber with 40mL of air further constrained 
the heart model, shifting the EDPVR leftward by about 100mL.  The low volume side of 
the EDPVR was consistently shifted downward by approximately 8cmH2O. 
 
 
Fig.  9  EDPVR of recoil component.  Trials denoted by a (*) were run with 20mL of air in the 
systolic support chamber. 




Fig.  10  EDPVR of biphasic modulation - support and recoil components. 
 




The results in the previous chapter clearly demonstrate the ability of the proposed 
combination support device to biphasically modulate the EDPVR of a model normal 
heart.  The diastolic recoil frame, the particular interest of this study, consistently created 
negative pressures at low volumes in all heart models used.  This pressure drop would 
lower the filling resistance in ventricles with high stiffness, increasing filling volume, 
decreasing filling time, and ameliorating diastolic dysfunction and the associated 
biochemical responses to it.  The constraint of the passive systolic support device on 
maximum filling volumes was also shown in these trials, shifting the EDPVR leftward.  
This size reduction would prevent overfilling and reduce the abnormal stresses on the 
heart, limiting adverse biochemical cascades and inhibiting or even reversing 
degenerative remodeling and the associated systolic dysfunction. 
 
The responses of the two models were very similar, although the maximum pressure 
obtained by the second model was higher because the non-elastic shell is rigid when 
pressurized, much like myocardium.  The volume limit of the heart model varied 
somewhat (250-350mL) between models, and even between trials as the model was 
often repaired or adjusted, affecting its size slightly.  Nevertheless, the shape of the 
EDPVR remained similar, and the responses to modulation by the device were 
consistent; therefore, although slight changes in model and prototype construction are 
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required to gain entirely consistent results, the goal of the bench-top study to provide a 
proof of the recoil augmentation concept was accomplished. 
 
During the study, it became evident that the support chamber cannot be simply secured 
at the top and bottom of the device and then allowed to freely inflate.  This configuration 
causes the chamber to fill unevenly, changing the shape of the cavity for the ventricles, 
and pushing the device off the ventricles.  The presence of the diastolic recoil frame 
largely negates this problem by maintaining the shape of the device.  This problem can 
be completely avoided by securing the inner wall to the outer wall along the arc length 
of the device at regular intervals, thereby forcing the inner chamber to maintain its shape 
during inflation. 
 
Upon implantation of the device in a live model, several factors will be of special 
interest.  The vacuum sac used in the model maintained a vacuum of 25 cm, and had no 
fluid between the device, model and sac.  Postoperatively, the vacuum in the pericardial 
sac is maintained mechanically until the entrance hole in the pericardial sac heals and it 
can maintain a vacuum on its own.  The pericardial sac is lubricated, which may 
substantially change the shear stresses acting on the device and holding it in place.  
Additionally, substantial fibrosis is expected to occur.  As discussed previously, the two 
layer design of the device allows the pericardium to fibrose to the outside of the device 
and the myocardium to fibrose to the inside, maintaining the heart’s freedom of 
movement. 
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Another factor of interest will be the difference in wall thickness between the left and 
right ventricles.  The model used in this study modeled the two ventricles as a whole, 
with no distinguishment between the left and right ventricles.  It is possible that the 
lower resistance of the right ventricle will absorb a proportionately larger amount of the 
device‘s constraint and recoil, inhibiting right ventricular function and dampening the 
effects on the left ventricle, although a previous unpublished study in sheep of the 
support prototype‘s efficacy did not indicate that this was a significant problem. 




Heart failure is a disease with a plethora of initial causes that ultimately result in a 
progressive failure cycle of decreased cardiac output, prolonged compensatory 
mechanisms, degenerative remodeling, and dysfunction.  The details of these steps vary 
based upon the cause of the disease, and the type of heart failure that develops, but the 
general cycle is the same.  Complete therapies for heart failure must not only address the 
underlying cause initiating this cycle, but must interrupt the self-perpetuating cycle 
itself.  The various pharmaceutics, surgeries and devices each have their own purpose 
and results, and may be combined to create a complete therapy.  Because of their ability 
to directly modulate the adverse mechanical loads the heart is experiencing and to 
indirectly affect the biochemical compensatory mechanisms, devices are an increasingly 
attractive and popular component of heart failure treatments. 
 
This investigation studied in vitro the addition of a recoil component to a passive 
systolic support device.  In a bench-top model of the ventricles, the device demonstrated 
an ability to provide bi-phasic modulation of the heart cycle.  At low volumes, 
corresponding to beginning diastole, the diastolic recoil component releases energy 
stored during compression to augment ventricular filling.  At high volumes, 
corresponding to end diastole, the systolic support component constrains the ventricles, 
preventing overfilling and allowing the myocardium to function more effectively.  The 
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diastolic recoil component prevents exacerbation of diastolic dysfunction by the 
constraint of the systolic support component.  The combined device provides passive 
support of the entire heart cycle.  Together with an active component that was not 
studied in these trials, the three main classes of cardiac devices synergistically combine 
to assist and support the heart.  This approach promises to induce restorative remodeling, 
increase cardiac output, reduce the compensatory response, and reduce diastolic and 
systolic dysfunction, reversing heart failure and leading to restoration of the heart. 
 
Further preclinical studies are required to study the efficacy and safety of the device in 
live animal models and the effects of the pericardium, fibrosis, and right ventricular 
dampening.  Results from these studies can then be used to refine the device prototype 
and lead into future clinical studies. 
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